FRA:BNN - Deutsche Boerse Ag - DE0005203947 - Common Stock - Currency: EUR
FRA:BNN (7/25/2025, 7:00:00 PM)
2.25
-0.08 (-3.43%)
The current stock price of BNN.DE is 2.25 EUR. In the past month the price increased by 14.8%. In the past year, price increased by 0.45%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
SIKA.DE | SIKA AG-REG | 26.86 | 35.82B | ||
GIN.DE | GIVAUDAN-REG | 29.29 | 34.97B | ||
6D81.DE | DUPONT DE NEMOURS INC | 17.44 | 26.79B | ||
DSFIR.AS | DSM-FIRMENICH AG | 93.85 | 23.44B | ||
BRG.OL | BORREGAARD ASA | 23.59 | 19.44B | ||
ELK.OL | ELKEM ASA | 31.49 | 15.70B | ||
SY1.DE | SYMRISE AG | 25.51 | 12.20B | ||
1COV.DE | COVESTRO AG | N/A | 11.43B | ||
AKZA.AS | AKZO NOBEL N.V. | 15.5 | 9.98B | ||
EVK.DE | EVONIK INDUSTRIES AG | 28.17 | 8.40B | ||
AMC.DE | ALBEMARLE CORP | N/A | 8.35B | ||
SYENS.BR | SYENSQO SA | 15.01 | 7.41B |
BRAIN Biotech AG is a technology company, which engages in the development and commercialization of bioactives, natural compounds, and proprietary enzymes. The company is headquartered in Zwingenberg, Hessen and currently employs 285 full-time employees. The company went IPO on 2016-02-09. Biotechnology Research and Information Network AG, is a Germany -based Company. The firm is a supplier of bio-based products and solutions such as enzymes and proteins, microbial production strains, natural substances, and biotechnological solutions for industrial processes in the areas of nutrition, health, and the environment. BRAIN Biotech is also offers contract research and development in the fields of enzyme technology, microbial strain development and bioprocess development.
BRAIN BIOTECH AG
Darmstaedter Strasse 34-36
Zwingenberg HESSEN DE
Employees: 296
Phone: 49625193310
The current stock price of BNN.DE is 2.25 EUR. The price decreased by -3.43% in the last trading session.
The exchange symbol of BRAIN BIOTECH AG is BNN and it is listed on the Deutsche Boerse Ag exchange.
BNN.DE stock is listed on the Deutsche Boerse Ag exchange.
9 analysts have analysed BNN.DE and the average price target is 5.83 EUR. This implies a price increase of 159.31% is expected in the next year compared to the current price of 2.25. Check the BRAIN BIOTECH AG stock analysts ratings, price target forecast and up-and down grades for more detailed information.
BRAIN BIOTECH AG (BNN.DE) has a market capitalization of 49.16M EUR. This makes BNN.DE a Nano Cap stock.
BRAIN BIOTECH AG (BNN.DE) currently has 296 employees.
BRAIN BIOTECH AG (BNN.DE) has a support level at 1.92 and a resistance level at 2.6. Check the full technical report for a detailed analysis of BNN.DE support and resistance levels.
The Revenue of BRAIN BIOTECH AG (BNN.DE) is expected to grow by 6.32% in the next year. Check the estimates tab for more information on the BNN.DE EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
BNN.DE does not pay a dividend.
BRAIN BIOTECH AG (BNN.DE) will report earnings on 2025-08-28.
BRAIN BIOTECH AG (BNN.DE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.63).
ChartMill assigns a technical rating of 5 / 10 to BNN.DE. When comparing the yearly performance of all stocks, BNN.DE is a bad performer in the overall market: 77.91% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to BNN.DE. Both the profitability and financial health of BNN.DE have multiple concerns.
Over the last trailing twelve months BNN.DE reported a non-GAAP Earnings per Share(EPS) of -0.63. The EPS decreased by -69.73% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -17.27% | ||
ROE | -227.22% | ||
Debt/Equity | 0.74 |
ChartMill assigns a Buy % Consensus number of 84% to BNN.DE. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 70.76% and a revenue growth 6.32% for BNN.DE